B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 187.6 DKK -2.75% Market Closed
Market Cap: 14.8B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Bavarian Nordic A/S
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bavarian Nordic A/S
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
B
Bavarian Nordic A/S
CSE:BAVA
Gross Profit
kr3.5B
CAGR 3-Years
91%
CAGR 5-Years
62%
CAGR 10-Years
19%
Genmab A/S
CSE:GMAB
Gross Profit
kr18.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Gross Profit
kr55.4m
CAGR 3-Years
-23%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Gross Profit
€277.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Gross Profit
kr24.1m
CAGR 3-Years
19%
CAGR 5-Years
6%
CAGR 10-Years
8%
Saniona AB
STO:SANION
Gross Profit
-kr22.9m
CAGR 3-Years
53%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Bavarian Nordic A/S
Glance View

Market Cap
14.6B DKK
Industry
Biotechnology

Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.

BAVA Intrinsic Value
509.91 DKK
Undervaluation 63%
Intrinsic Value
Price
B

See Also

What is Bavarian Nordic A/S's Gross Profit?
Gross Profit
3.5B DKK

Based on the financial report for Jun 30, 2024, Bavarian Nordic A/S's Gross Profit amounts to 3.5B DKK.

What is Bavarian Nordic A/S's Gross Profit growth rate?
Gross Profit CAGR 10Y
19%

Over the last year, the Gross Profit growth was -6%. The average annual Gross Profit growth rates for Bavarian Nordic A/S have been 91% over the past three years , 62% over the past five years , and 19% over the past ten years .

Back to Top